Business Wire

The Trust Gap: Companies value digital trust but little progress is being made to implement it

29.5.2024 17:46:00 EEST | Business Wire | Press release

Share

As organisations purse digital transformation, they urgently need to prioritise digital trust to achieve their goals and prepare for future market opportunities, legislation, and regulatory compliance. New research from ISACA, the leading global professional association helping individuals and organisations in their pursuit of digital trust, reveals critical gaps in organisational strategies regarding digital trust.

The ISACA State of Digital Trust 2024 report finds that 77% of respondents agree that digital trust is crucial to digital transformation and 82% say digital trust will grow in importance over the next five years. Despite this recognition, almost three quarters (71%) report that their organisation provides no staff training on digital trust and only 21% of organizations are planning to increase their budget for digital trust.

Most (76%) business and IT professionals believe digital trust is relevant to their organisation and 65% say it is important that organisations be independently graded on digital trust practices, with the results made publicly available. ISACA defines digital trust as the confidence in the integrity of the relationships and transactions between providers and consumers within a digital ecosystem and is a key indicator of an organisation’s security credentials.

Despite recognising its relevance and importance, three quarters (75%) of respondents are either unsure or not fully aware of what improving digital trust requires in practice. A similar number (77%) report that their organisations do not currently measure the maturity of their digital trust practices or are unsure if they do.

Chris Dimitriadis, Chief Global Strategy Officer at ISACA, said: “It’s encouraging that businesses continue to recognise the importance of digital trust, not just for business sustainability, security, and profitability, but for building long-term consumer trust. Yet more needs to be done to truly achieve high levels of digital trust, which starts with measuring current levels to establish a benchmark and create a maturity plan.”

39% of organisations admit they are experiencing more cyberattacks, and 15% are suffering from more privacy breaches compared to a year ago. And this is only going to get worse if businesses don’t prioritise digital trust. Respondents recognise that organisations with low digital trust are more likely to see a reputation decline (64%), suffer from more cybersecurity incidents (58%), experience more privacy breaches (57%) and even lose customers (54%). The survey reveals that the biggest obstacles to achieving high levels of digital trust include a lack of staff skills and training (50%), lack of buy-in from leadership (42%), and insufficient processes and governance practices (32%).

Dimitriadis adds: “It is not down to business leaders alone to lead the charge - digital trust practices should be implemented and aligned across all departments to truly succeed. Our survey has found that many businesses are unsure on what improving digital trust requires in practice, but working with a trusted partner who can provide a step-by-step framework and assist in digital trust training can set the business on the right path to success and security.”

Leveraging Tools and Frameworks to Advance Trust

According to the survey, only 15 percent of respondents’ organizations currently use a framework for their digital trust practices, but almost half (46 %) of respondents believe it is extremely/very important for an organisation to have a digital trust framework. ISACA recently launched its Digital Trust Ecosystem Framework (DTEF), a comprehensive digital trust resource with indicators and controls that can be used and customised for the needs of all organisations. The DTEF roadmap and implementation guides provide a clear understanding of how organisations can attain the level of digital trust that fits their business models, strategies, and goals.

The top three benefits of using a framework include saving time and effort, enabling benchmarking with other organisations in a cost-efficient way, and providing added credibility and third-party validation in support of budget and staff requests.

Notes to Editors

All figures are based on fieldwork conducted by ISACA between 12th and 30th January 2024, amongst a total of 1,161 business and IT professionals in Europe. In total, ISACA surveyed 5,870 business and IT professionals worldwide.

About ISACA

ISACA® (www.isaca.org) is a global community advancing individuals and organizations in their pursuit of digital trust. For more than 50 years, ISACA has equipped individuals and enterprises with the knowledge, credentials, education, training and community to progress their careers, transform their organizations, and build a more trusted and ethical digital world. ISACA is a global professional association and learning organization that leverages the expertise of its 180,000 members who work in digital trust fields such as information security, governance, assurance, risk, privacy and quality. It has a presence in 188 countries, including 225 chapters worldwide. Through the ISACA Foundation, ISACA supports IT education and career pathways for underresourced and underrepresented populations.

Twitter: www.twitter.com/ISACANews
LinkedIn: www.linkedin.com/company/isaca
Facebook: www.facebook.com/ISACAGlobal
Instagram: www.instagram.com/isacanews

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Firstlight Group
+44 7960 079 643, isacateam@firstlightgroup.io

ISACA
Esther Almendros, +34 692 669 772, ealmendros@isaca.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye